In a major breakthrough in the fight against HIV, the European Medicines Agency (EMA) has recommended the approval of lenacapavir, a twice-yearly injectable drug developed by Gilead Sciences and ...

Gilead receives positive CHMP opinions under accelerated review from EMA for twice-yearly lenacapavir for HIV prevention: Foster City, California Saturday, July 26, 2025, 13:00 Hr ...

HIV funding cuts. 820 words. 2 photos available. PHOENIX – Ending the spread of HIV in Arizona may become more difficult if ...

Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the ...

In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York. People who were impacted developed unusual infections and grew sick as their ...

Countries worldwide must step up to support the fight against HIV or face the “ticking time bomb” left by the wholesale ...

DAP Health is presenting “Next Gen Care: Innovations in HIV Prevention,” an event that will highlight cutting-edge care and ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

Declining investment in global health surveillance, research, and scientific innovation are happening as the need for vigilance has never been greater, writes Robert C. Gallo.